Danaher Corporation reported its fourth-quarter earnings for 2024, revealing an adjusted earnings per share (EPS) of $2.14, slightly below the estimated $2.16. The company's revenue for the quarter reached $6.54 billion, surpassing expectations of $6.39 billion, marking a 2% increase year-over-year. However, the BioTech segment generated revenues of $1.87 billion, falling short of the anticipated $1.88 billion. For the full year 2024, Danaher reported net earnings of $3.9 billion, with total revenues remaining flat at $23.9 billion compared to the previous year. The company also highlighted operating cash flow of $6.7 billion for FY 2024. In terms of guidance, Danaher anticipates core revenue growth of approximately 3% for 2025, although it expects a 2% revenue headwind due to the strengthening U.S. dollar. The stock fell approximately 3% in pre-market trading following the earnings announcement.